Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom

BACKGROUND: Sunitinib and pazopanib are the only two targeted therapies for the first-line treatment of locally advanced or metastatic renal cell carcinoma (mRCC) recommended by the United Kingdom’s National Institute for Health and Care Excellence. Pazopanib demonstrated non-inferior efficacy and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Amdahl, Jordan, Diaz, Jose, Sharma, Arati, Park, Jinhee, Chandiwana, David, Delea, Thomas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479501/
https://www.ncbi.nlm.nih.gov/pubmed/28636648
http://dx.doi.org/10.1371/journal.pone.0175920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479501/
https://www.ncbi.nlm.nih.gov/pubmed/28636648
http://dx.doi.org/10.1371/journal.pone.0175920

Ejemplares similares